PLUS THERAPEUTICS INC (PSTV)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$3.10+2.65%
Close 2026-08-27 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · PSTV
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -63.1% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 117 industry peers · Company calendar date is not available
PSTV — debt issuance
Dated 2026-06-05
Entry into a Material Definitive Agreement. On June 1, 2026, Plus Therapeutics, Inc. (the “Company”) entered into an Equity Distribution Agreement (the “Distribution Agreement”) with Canaccord Genuity LLC (the “Agent”), pursuant to which the Company may issue and sell, from time to time (the “Offering”), shares of its common stock, par value $0.001 per share (the “Common Stock”), having an aggregate offering price of up to $17,350,000 (the “Shares”), depending on market demand, with the Agent…
Why it matters: More covered lives would build on the midyear goal already met. The company also aims to grow orders and launch more tests.
Supportive ifThe company reports U.S. payer coverage above 150 million covered lives.
Worry ifThe company reports coverage at or below 150 million lives, or says a payer agreement was lost.
Why it matters: Full enrollment keeps the trial on the stated path to data in Q1 2027 and an FDA meeting after the readout.
Supportive ifThe company reports that ReSPECT-GBM Phase 2 enrollment is complete during 2026.
Worry ifThe company reports that enrollment is incomplete by December 31, 2026. Or it delays the planned Q1 2027 data readout.
Why it matters: First dosing would show the pediatric brain cancer study has moved from site setup to treating patients.
Supportive ifThe company confirms the first patient received a dose in ReSPECT-PBC by September 30, 2026.
Worry ifThe company reports no first dose by September 30, 2026, or says the trial start has been delayed.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$320 on $10,000 · ±3.2% | How much price usually moves either way. |
| Bad day | $947 loss on $10,000 · 9.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,687 loss on $10,000 · 86.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.